# ExoProTher Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exoprother-medical

- Industry: Biotechnology
- Headquarters: Nesher, Israel
- Website: www.exoprother.com/
- Latest round: Seed (Nov 1, 2022)
- Investors on record: 1

## About

Based in Israel, and founded in 2017 by Alex Tendler (CTO) and Lana Volokh (CEO), ExoProTher Medical operates as a biomedical company that develops and offers novel therapies for the treatment of cancer in humans. In August 2023, ExoProTher Medical raised venture funding from investors Israel Biotech Fund and Peregrine Ventures. As of June 2024, the company is in the preclinical stage of development. 

The firm’s cancer treatment method focuses on the delivery of healthy p53 protein into tumor cells. This approach targets the p53 tumor suppression mechanism, which is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small-cell lung cancers. ExoProTher aims to restore the body's natural tumor suppression function with minimal side effects by utilizing exosomes and natural nano-particles produced by living cells.

## Funding rounds

- Seed, Nov 1, 2022 — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed